Fat exposure raised OPA1 in male mice and not females. An approved obesity drug then worked much more weakly in OPA1-deficient females — which is the finding with practical teeth.
Abdominal obesity alone: 47% higher mortality risk. Vitamin D deficiency alone: up to 91%. Both together: 123% — more than either, and the researchers propose a reason the two interact.
Activate GIPR in the brainstem and appetite falls. Block it in the hypothalamus and fullness signals work better. Two opposite drugs, two circuits, same outcome — and two companies betting on each.
Polyamines turn out to be iron storage lockers. Cancer cells need high polyamine levels to grow — which may be exactly what makes them vulnerable to having those lockers opened.
A cell therapy is worthless if the cells arrive dead. Repligen is paying $1.5 billion for the freezing media that keep them alive between factory and patient.
Autopsy data from thousands of women: 18% of hormone therapy users showed no Alzheimer’s pathology versus 10% of non-users. The women studied started therapy around 70, not 50 — which matters enormously.
Photodynamic therapy needs molecules that behave correctly in excited states — which is precisely the calculation classical computers handle worst, and quantum computers should handle best.
Omega fats entered natural killer cells through a receptor called LRP5 and dialled down the metabolism those cells need to attack tumours. Deleting the receptor made them better killers.
A onetime genetic-medicine pioneer went bankrupt, and its Fabry gene therapy went to auction. PTC paid $111 million upfront for an asset heading into an FDA submission.
5,500 samples measured across thousands of proteins each, released publicly. Parkinson’s is still diagnosed by watching people move — this is an attempt to define it biologically instead.
The trial was stopped early for efficacy — and lands in a subtype that had almost nothing five years ago and now has three approved drugs competing.
A molecular glue that makes the cell’s own disposal machinery destroy cancer-driving proteins rather than merely blocking them — and the first of its class to reach patients.